Study to Assess Pharmacokinetics, Safety, and Tolerability of Saroglitazar Magnesium in Adults with Moderate Hepatic Impairment Due to Cholestatic Liver Disease
Led by Zydus Therapeutics Inc. · Updated on 2026-09-14
6
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the pharmacokinetics, safety, and tolerability of Saroglitazar Magnesium given every other day to adults with moderate liver impairment caused by cholestatic liver disease and cirrhosis. This phase 1, open-label, single-arm study aims to understand how the drug behaves in the body and its safety profile in this specific group of patients.
Participants receive Saroglitazar Magnesium 1 mg orally in the morning before breakfast without food, every other day for 29 days. The study focuses on detailed blood sampling on Day 1 and Day 29 to measure drug levels at multiple time points to assess how the drug is absorbed, distributed, metabolized, and eliminated.
During the trial, participants undergo frequent pharmacokinetic blood tests to measure drug concentration and metabolism markers over 48 hours after dosing on specific days. Researchers also monitor safety by recording any adverse events throughout the 35-day study period. Laboratory tests, including liver enzyme levels, are evaluated from baseline through the treatment to assess changes and tolerability.
CONDITIONS
Brief Title
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
Research Team
F
Farheen Shaikh
D
Deven Parmar
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Saroglitazar (investigational)
UDCA (standard care context)
What it is
An open‑label, single‑group study evaluating pharmacokinetics and safety of oral Saroglitazar Magnesium 1 mg in adults with moderate hepatic impairment due to cholestatic liver disease
Ursodeoxycholic acid is an established first‑line therapy for cholestatic liver disease such as primary biliary cholangitis
Not part of this study; reflects typical clinical treatment outside the trial
Primary purpose
To assess pharmacokinetics and safety/tolerability in moderate hepatic impairment due to cholestatic liver disease
Used to slow progression of cholestatic liver disease by improving bile flow
How it is given
Oral Saroglitazar Magnesium 1 mg assigned to all participants on alternate‑day dosing as per protocol
Oral ursodeoxycholic acid taken daily as standard therapy
Current evidence base
Pharmacokinetic and safety data are being collected; no efficacy outcomes yet
Proven to improve biochemical response and slow disease progression in PBC
Important risks
Safety is under evaluation; risk profile in moderate hepatic impairment not yet established
Generally well tolerated with few adverse effects over long‑term use
Important limitations
Small single‑arm study, limited to pharmacokinetics and safety in moderate impairment; not designed to assess clinical benefit
Efficacy mainly studied in primary biliary cholangitis; effects in other cholestatic conditions may vary
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 80Years
All Genders
Eligibility Criteria
You may qualify if you...
Male or female aged 18 to 80 years at consent
Body mass index between 18.0 and 48.0 kg/m2 at screening
Able to swallow and retain oral medication
Documented moderate hepatic impairment with cirrhosis due to cholestatic liver disease with Child-Pugh score 7 to 9
Laboratory values within acceptable ranges including alkaline phosphatase above normal, liver enzymes up to 10 times normal, neutrophils at least 750/mm3, platelets at least 25,000/mm3, hemoglobin at least 8 g/dL, and specific alpha-fetoprotein limits with negative imaging for liver cancer
Provide written informed consent and agree to follow the study protocol
You will not qualify if you...
Unstable or significant medical condition that prevents participation
History of malignancy within 3 years except certain skin or in situ cancers
Stomach or intestinal surgery within 6 months that affects drug absorption, except minor surgeries
Clinically relevant drug allergy such as anaphylaxis
Major surgery within 3 months
Blood or blood product donation within 3 months
Active infection requiring treatment or symptoms within 2 weeks
Use of investigational drugs within 30 days or 5 half-lives before study drug
Poor kidney function with estimated glomerular filtration rate below 45 mL/min/1.73 m2
Poor peripheral venous access
Blood product receipt within 1 month
Positive HIV-1 antibody test
Other liver diseases such as non-alcoholic or alcoholic steatohepatitis, autoimmune hepatitis, or viral hepatitis
Significant liver disease status change within 30 days
Recent gastrointestinal bleeding, functioning organ transplant, or severe ascites requiring frequent paracentesis
Pregnant or lactating females or unwillingness to use effective contraception during and one month after study
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 29 days
Participants take Saroglitazar Magnesium 1 mg orally every other day in the morning before breakfast without food for 29 days.
Regular blood sampling on Day 1 and Day 29 for pharmacokinetic assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Evaluating Whole Genome Sequencing to Find Genetic Causes of Adult-Onset Cholestatic Liver Disease
A Study of Adults Aged 18 to 65 with Unexplained or Atypical Cholestasis
Study to Assess Pharmacokinetics, Safety, and Tolerability of Saroglitazar Magnesium in Adults with Moderate Hepatic Impairment Due to Cholestatic Liver Disease
Study of Genetic Mutations Linked to Familial Intrahepatic Cholestasis and Their Role in Hepatobiliary Cancers and Chronic Liver Diseases
Phase 1 Open-Label Study of Saroglitazar Magnesium in Adults with Hepatic Impairment and Cirrhosis Due to Cholestatic Liver Disease
Comparing Vitamin D2 Alone Versus Vitamin D2 Plus Calcitriol to Improve Vitamin D Levels in Children With Cholestatic and Chronic Liver Disease
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment.